phase 1_completion
saveBeOne Medicines AG — BG-89894 (Phase I Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Advanced Malignancy, Bladder Cancer, Esophageal Cancer, Gastric Cancer, Liver Cancer, Malignant Mesothelioma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Solid Tumor
Data sources
globaldata
Found something off?
same company · ±60 days · 2
related news · 5
- biopharma diveBiotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
- endpointsBeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
- endpointsBeOne culls five cancer programs and an autoimmune Phase 2
- endpointsBeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
- biopharma diveBiotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
comments(0)
5-min edit window · permanent after that